Korttids hepatitt C-behandling av heroinavhengige pasienter

Kristensen, Øistein; Sundøy, Anders; Skeie, Karin; Vederhus, John‐Kåre; Øye, Ingebjørg; Opsal, Anne; Rysstad, Ole; Gallefoss, Frode

doi:10.4045/tidsskr.09.33690

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En viktig faktor i dette regnskapet er infeksjonens naturlige forløp. Mange oversiktsartikler og laerebøker nevner nokså sjablongmessig at 20 % av pasientene får levercirrhose etter 20 år (4,5). Dette er antakelig et altfor høyt anslag.…”

unclassified

Er hepatitt C viktig for stoffmisbrukerne?

Aavitsland¹

2009

Tidsskriftet

View full text Add to dashboard Cite

Er hepatitt C viktig for stoffmisbrukerne?1623 Stoffmisbrukere har mange helseproblemer. Hepatitt C kan vaere et av de minste, og fordeler og ulemper med tidlig antiviral behandling må vurderes nøye Vi har alle sett dem i sommergatene, stoffmisbrukerne, der de sitter og tigger penger eller selger gatemagasiner, hvileløst tripper rundt og speider etter doplangeren eller halter ustøtt av gårde til en mørk del av parken for å sette en sprøyte. Kommer vi naer nok, kan vi med et kort blikk diagnostisere avmagring, elendig tannstatus og abscesser. «Helsen er like skrøpelig blant misbrukerne som blant folk i den tredje verden,» sier en erfaren lege ved Feltpleien i Oslo (1).

show abstract

unclassified

Er hepatitt C viktig for stoffmisbrukerne?

Aavitsland¹

2009

Tidsskriftet

View full text Add to dashboard Cite

show abstract

A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region

et al. 2014

View full text Add to dashboard Cite

BackgroundFifteen million adults in the World Health Organization European Region are estimated to have active hepatitis C infection. Intravenous drug use is a major hepatitis C transmission route in this region, and people who inject drugs (PWID) constitute a high-risk and high-prevalence population. A systematic review was conducted to assess levels of hepatitis C treatment uptake among PWID in Europe.MethodsSearches in MEDLINE and EMBASE were carried out for articles in any language published between 1 January 2000 and 31 December 2012. Articles were included in the review if they presented original research findings about hepatitis C treatment uptake levels among people who reported injecting drugs currently or formerly, as well as those who reported using drugs currently or formerly (mode of consumption not specified). Treatment uptake data were extracted if uptake was measurable in relation to the number of patients who either: (a) tested HCV antibody-positive; (b) tested positive for HCV-RNA; or (c) tested positive for HCV-RNA and met additional treatment criteria.ResultsTwenty-five articles from 12 countries were included in the review. Among groups of drug-using study participants who were hepatitis C antibody-positive, the median treatment uptake level was 17%, and among those who were hepatitis C RNA-positive, the median was 30%. In the 11 studies reporting specifically on treatment uptake among current and former injecting drug users, hepatitis C RNA-positive study populations had a median treatment uptake level of 32%. Only one study reported on treatment uptake for current drug users.ConclusionsThis systematic review indicates that hepatitis C treatment uptake is relatively low among drug users in several European countries, and also points to considerable knowledge gaps regarding treatment uptake levels in this population. There was large variability in treatment uptake levels, suggesting that there may be major differences between and within countries in relation to treatment availability, drug-using populations in need of treatment, and the existence of integrated health care services targeting drug users. Stronger national hepatitis C treatment policies are needed, along with efforts to increase knowledge and reduce misconceptions among physicians regarding the feasibility and importance of treating drug users who have hepatitis C.

show abstract

Hepatitt C er viktig for stoffmisbrukerne!

Krook¹

2009

Tidsskriftet

View full text Add to dashboard Cite

show abstract

Korttids hepatitt C-behandling av heroinavhengige pasienter

Cited by 3 publications

References 14 publications

Er hepatitt C viktig for stoffmisbrukerne?

Er hepatitt C viktig for stoffmisbrukerne?

A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region

Hepatitt C er viktig for stoffmisbrukerne!

Contact Info

Product

Resources

About